1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
17.97%
Cash & equivalents growing 17.97% while Drug Manufacturers - Specialty & Generic shows decline of -13.57%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Below half the Drug Manufacturers - Specialty & Generic median of -8.62% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
3.22%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-0.36%
Inventory growth less than half of Drug Manufacturers - Specialty & Generic median of 3.62%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
No Data
No Data available this quarter, please select a different quarter.
13.36%
Below half the Drug Manufacturers - Specialty & Generic median of -2.89%. Jim Chanos would question if the company faces working capital strain.
-5.83%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.29%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-0.89%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-5.27%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.61%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-2.32%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of -1.43%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-9.06%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
142.30%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1414.01%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
0.76%
Below half the Drug Manufacturers - Specialty & Generic median of -0.54%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
2.62%
Below half the Drug Manufacturers - Specialty & Generic median of -1.78%. Jim Chanos might see potential stagnation or distress vs. peers.
10.55%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.75%. Jim Chanos might see a warning sign of stressed supplier payments.
-4.15%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
6.34%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-11.26%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-4.42%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-2.53%
50-75% Drug Manufacturers - Specialty & Generic median of -4.65%. Mohnish Pabrai notes fewer yoy liability expansions.
7.45%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-4.54%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-6.28%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
3.85%
Below half Drug Manufacturers - Specialty & Generic median of -0.54%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.08%
Below half Drug Manufacturers - Specialty & Generic median of -2.90%. Joel Greenblatt sees a much lower liability expansion vs. peers.
13.21%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-7.63%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.53%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-283.99%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
2.88%
Below half Drug Manufacturers - Specialty & Generic median of -0.02%. Jim Chanos suspects slower net worth growth or losses vs. peers.
2.62%
Below half Drug Manufacturers - Specialty & Generic median of -1.89%. Jim Chanos suspects a major slowdown or distress.
-9.06%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
5.45%
Below half Drug Manufacturers - Specialty & Generic median of -1.26%. Joel Greenblatt sees a stronger deleveraging trend than peers.
-19.59%
Below half of Drug Manufacturers - Specialty & Generic median 7.25%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
